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Valsalva-induced cluster headache
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Abstract A case valsalva-induced
cluster headache is presented.
Cluster attacks induced by valsal-
va manoeuvres alone were only
recently described, and such
patients have features of cough
headache and cluster headache.
Attacks occurred a couple of
times a week in the patient
presented, solely triggered by val-
salva manoeuvres including
coughing, sneezing or straining
and not by exercising.
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Cluster attacks of severe unilateral short-lived pain and
autonomic features have few identified triggers. Attacks
are described as occurring during vulnerable periods of
time rather than being induced by triggers, with the excep-
tion of alcohol ingestion during vulnerable periods. In
addition, cough-induced headache is uncommon but well
described, and is not prolonged or associated with auto-
nomic features. The presentation of valsalva-induced clus-
ter headache has characteristics of both cough headache
and cluster headache.
Case report
A 59-year-old man was evaluated for a 9-month history of
headache attacks precipitated only by coughing, sneezing
or, straining (for example while carrying heavy objects),
which are all valsalva manoeuvres. Attacks lasted 30–120
min, with a frequency of a couple of times a week and
were not triggered by his regular jogging. The side-locked
pain was centred in the right periorbital region and
between attacks there was a vague sensation in the same
area. Triggers such as a sneeze would rapidly bring on
severe sharp right periorbital pain and tearing, conjuncti-
val injection with frequent right-sided rhinorrhoea (no
congestion). There was no ptosis and at times the patient
was agitated, resulting in pacing. More than one attack
could be experienced in the same day. Although it was
clear that brief increases in intrathoracic pressure could
trigger an attack, the mildest forms of valsalva manoeuvre
(lifting objects, mild straining at stool, but not sneezing or
coughing) were usually free of attacks.
Background medical history was notable for a deep
vein thrombosis and a pulmonary embolus, which devel-
oped a few months after the start of the headaches.
Investigations failed to reveal any explanation for the
hypercoagulability and he was maintained on coumadin.
The patient did not have the factor V Leiden (R506Q)
mutation or the prothrombin G20210A mutation for hyper-
coagulability. Protein-C and protein-S levels were not
obtained, as the patient was already on coumadin and the
levels would be expected to be low. There was no history
of hypertension. The patient had stopped smoking 20 years
previously but had a ten pack-year history of smoking,
which ceased 20 years ago. General and neurological
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examinations were unremarkable. Specifically there was
no allodynia or sensory loss in the face. Brain magnetic
resonance imaging (MRI) was normal and there was no
Chiari type-1 malformation, posterior fossa crowding or
evidence of venous sinus thrombosis. Magnetic resonance
angiography of the brain was also normal.
The patient had discontinued a modest dose of vera-
pamil (240 mg daily) due to lack of response prior to ini-
tial review. A trial of topiramate prophylaxis was stopped
at 75 mg daily due to side effects and lack of response.
Sumatriptan 4 mg subcutaneous injection for abortive
relief was prescribed and used only once with moderate
relief. Prophylaxis then consisted of melatonin 3 mg
nightly (increasing to 6 mg) and by two weeks the fre-
quency of attacks reduced. Improvement continued over
the following 2 weeks. Over the following 4 weeks the
patient became attack-free. After 8 weeks the medication
was discontinued and and at the time of writing 12 weeks
off medication he has not had a recurrence.
Comments
Valsalva-induced cluster headache was first described by
Ko and Rozen [1]. Their patient had attacks typically last-
ing 4 h, solely triggered by valsalva manoeuvres and
responding to daily indomethacin. An earlier paper
described ‘benign cough cluster headache’ in a man with
unilateral headache attacks lasting only 1–10 min without
autonomic features, characteristics that do not favour a
diagnosis of cluster headache [2].
Attacks of cluster headache are not typically associat-
ed with an identified trigger, although alcohol is well
known to precipitate attacks. Valsalva triggers to headache
suggest a diagnosis of cough headache, which warrants
scrutiny of the posterior fossa and foramen magnum by
MRI for evidence of crowding and Chiari type-1 malfor-
mation. Without such abnormalities primary cough
headache is ascribed to presentations that fulfil Interna-
tional Headache Society criteria with headache lasting
from 1 s to 30 min only and without autonomic features
[3]. The patient presented had much longer attacks than
primary cough headache and the autonomic features fur-
ther separate primary cough headache from valsalva-
induced cluster headache. The patient’s frequent unevent-
ful jogging excludes primary exertional headache.
Secondary cluster-like headache has recently been
associated with cerebral vein thrombosis [4]. Magnetic
resonance venography was not performed in the case pre-
sented. The development of cerebral vein thrombosis
causing cluster headache and persisting for many months
despite anticoagulation was thought to be remote.  
Valsalva manoeuvres reliably increase intracranial
pressure by increasing central venous pressure, but rarely
is this accompanied by headache. The pathophysiology
bridging the rise in central venous pressure to the precip-
itous onset of cough headache or in this case a cluster
attack is unknown. Although exact mechanisms of cough
headache are unknown, response to lumbar puncture and
acetazolamide have suggested a role for raised intracranial
pressure. Cluster headache is easily provoked with nitro-
glycerin 1 mg sublingually but the delay of 30 to 50 min
suggests a different mechanism to cough for instance [5].
Indomethacin, a first line agent for cough headache,
was avoided, as the patient was anticoagulated. For the
same reason measurement of cerebrospinal fluid pressure
(CSF) was avoided. A related compound, melatonin,
which also has analgesic and anti-inflammatory effects,
among other actions, was started [6]. Melatonin has been
shown in a double-blind placebo-controlled study to be of
benefit in cluster headache [7]. Indomethacin is known to
reduce CSF pressure due to cerebral vasoconstriction and
a reduction in cerebral blood flow. It is not known whether
melatonin also reduces CSF pressure, but a recent small
study suggested that it does not reduce cerebral blood
flow [8]. The patient so far has not exhibited a return of
events off melatonin, but we cannot assume that he was
melatonin responsive, as a natural remission may have
occurred. Event-related triggers of cluster are uncommon
and valsalva-induced cluster is a distinct subtype of clus-
ter headache.
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